BioSpace News Archive

RenovoRx, Inc today highlights a presentation of a clinical data abstract at the recent 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting, held March 23-27, 2024 in Salt Lake City, Utah.

Nacuity Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing novel treatments for retinitis pigmentosa, cataract, and other diseases caused by oxidative stress, announced the appointment of Emmett T. Cunningham, Jr., M.D., Ph.D., MPH, to its board of directors.

Turnstone Biologics Corp. today announced the appointment of industry veteran William Waddill to the Company’s Board of Directors.

Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”) today announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. patent 10,143,419 (‘419 patent) entitled “Systems and Methods for Treating Cancer and/or Augmenting Organ Function.”

Apotex Inc. announced today that Allan Oberman, President & CEO, will be presenting at the 2024 Bloom Burton & Co. Annual Healthcare Investor Conference on Wednesday, April 17th, 2024 at 11:30 am EST.

Aesculap, Inc., a market leader in sterile container systems, has launched AESCULAP Aicon® RTLS, which pairs real-time location service technology with the AESCULAP Aicon® Sterile Container System to help improve the efficiency of Sterile Processing Departments.

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that Prenatal Diagnosis has published a study.

Annoviant™, Inc. proudly announces receipt of a $2.99 million grant from the National Institutes of Health.

At this year’s Interphex, ACG Engineering, part of ACG - the world’s only integrated pharmaceutical solutions and manufacturing company - will be focusing on its cost-effective approach to taking generics to market.

OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that the Hart-Scott-Rodino waiting period has expired with respect to its global license with AbbVie to develop OSE-230, a monoclonal antibody designed to resolve chronic and severe inflammation, currently in the pre-clinical development stage.